$KZR
Kezar Life Sciences, Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024031494 Filed on March 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $7.000M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.760M $26.54M
YoY Change 11.3% 31.69%
% of Gross Profit
Research & Development $17.17M $22.64M $85.70M
YoY Change -6.26% 52.38% 68.0%
% of Gross Profit
Depreciation & Amortization $260.0K $280.0K $1.066M
YoY Change 0.39% -198.94% 4.2%
% of Gross Profit
Operating Expenses $23.71M $28.40M $118.4M
YoY Change -3.32% 41.77% 66.41%
Operating Profit -$23.71M -$111.4M
YoY Change -3.32% 56.58%
Interest Expense $400.0K $2.329M $1.550M
YoY Change 8.11% 25.69% 30.8%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$32.26M -$101.9M
YoY Change 77.44% 49.28%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$21.66M -$32.26M -$101.9M
YoY Change -2.44% 77.44% 49.28%
Net Earnings / Revenue -1455.29%
Basic Earnings Per Share -$0.30 -$1.40
Diluted Earnings Per Share -$0.30 -$0.44 -$1.40
COMMON SHARES
Basic Shares Outstanding 72.80M 72.69M 72.55M
Diluted Shares Outstanding 72.80M 72.55M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $179.8M $201.4M $201.4M
YoY Change -30.22% -27.19% -27.19%
Cash & Equivalents $33.03M $35.49M $35.49M
Short-Term Investments $146.8M $165.9M $165.9M
Other Short-Term Assets $2.760M $3.287M $3.287M
YoY Change 255.21% 257.28% -64.12%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $185.6M $207.0M $207.0M
YoY Change -30.02% -27.57% -27.57%
LONG-TERM ASSETS
Property, Plant & Equipment $3.652M $3.912M $8.690M
YoY Change -21.56% 14.02% -34.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.501M $5.595M $5.595M
YoY Change 8.12% 730.12% 730.12%
Total Long-Term Assets $13.52M $14.29M $14.29M
YoY Change -28.66% 3.17% 3.17%
TOTAL ASSETS
Total Short-Term Assets $185.6M $207.0M $207.0M
Total Long-Term Assets $13.52M $14.29M $14.29M
Total Assets $199.1M $221.2M $221.2M
YoY Change -29.93% -26.15% -26.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.059M $8.251M $8.251M
YoY Change 22.32% 232.84% 232.84%
Accrued Expenses $6.664M $6.481M $9.493M
YoY Change -2.52% 8.87% 11.45%
Deferred Revenue
YoY Change
Short-Term Debt $1.304M $0.00 $0.00
YoY Change
Long-Term Debt Due $1.304M $0.00
YoY Change
Total Short-Term Liabilities $16.16M $17.74M $17.74M
YoY Change 18.45% 61.35% 61.35%
LONG-TERM LIABILITIES
Long-Term Debt $8.829M $10.07M $10.07M
YoY Change -10.76% 2.39% 2.39%
Other Long-Term Liabilities $5.019M $5.852M $5.852M
YoY Change -38.44% -33.99% -33.99%
Total Long-Term Liabilities $8.829M $10.07M $15.92M
YoY Change -10.76% 2.39% -14.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.16M $17.74M $17.74M
Total Long-Term Liabilities $8.829M $10.07M $15.92M
Total Liabilities $30.01M $33.67M $33.67M
YoY Change -5.3% 13.37% 13.37%
SHAREHOLDERS EQUITY
Retained Earnings -$372.4M -$350.8M
YoY Change 37.37% 40.94%
Common Stock $541.9M $538.5M
YoY Change 3.39% 3.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $169.1M $187.6M $187.6M
YoY Change
Total Liabilities & Shareholders Equity $199.1M $221.2M $221.2M
YoY Change -29.93% -26.15% -26.15%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$21.66M -$32.26M -$101.9M
YoY Change -2.44% 77.44% 49.28%
Depreciation, Depletion And Amortization $260.0K $280.0K $1.066M
YoY Change 0.39% -198.94% 4.2%
Cash From Operating Activities -$22.86M -$18.98M -$81.65M
YoY Change 9.6% 19.5% 38.74%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $1.000K $1.810M
YoY Change -100.0% -99.71% 14.7%
Acquisitions
YoY Change
Other Investing Activities $20.41M $27.88M $77.86M
YoY Change 22.29% -435.16% -186.69%
Cash From Investing Activities $20.41M $27.88M $76.05M
YoY Change 24.51% -421.88% -183.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 59.00K 638.0K
YoY Change -100.0% -88.34% -99.5%
NET CHANGE
Cash From Operating Activities -22.86M -18.98M -81.65M
Cash From Investing Activities 20.41M 27.88M 76.05M
Cash From Financing Activities 0.000 59.00K 638.0K
Net Change In Cash -2.461M 8.957M -4.963M
YoY Change -43.12% -137.26% -77.87%
FREE CASH FLOW
Cash From Operating Activities -$22.86M -$18.98M -$81.65M
Capital Expenditures $0.00 $1.000K $1.810M
Free Cash Flow -$22.86M -$18.98M -$83.46M
YoY Change 8.06% 16.98% 38.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001645666
CY2020 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-38542
CY2023 dei Entity Registrant Name
EntityRegistrantName
Kezar Life Sciences, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3366145
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
4000 Shoreline Court
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2023 dei City Area Code
CityAreaCode
650
CY2023 dei Local Phone Number
LocalPhoneNumber
822-5600
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2023 dei Trading Symbol
TradingSymbol
KZR
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
173000000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
72801359
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 kzr Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2023Q4 kzr Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
185
CY2023 dei Auditor Name
AuditorName
KPMG LLP
CY2023 dei Auditor Location
AuditorLocation
San Francisco, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35493000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40456000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
165879000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
236105000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5578000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9161000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
206950000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
285722000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3912000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3431000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4778000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9741000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5595000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
674000
CY2023Q4 us-gaap Assets
Assets
221235000
CY2022Q4 us-gaap Assets
Assets
299568000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8251000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2479000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6481000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5953000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3012000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2565000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17744000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10997000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5852000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8865000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10069000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9834000
CY2023Q4 us-gaap Liabilities
Liabilities
33665000
CY2022Q4 us-gaap Liabilities
Liabilities
29696000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72779077
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72779077
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68493429
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68493429
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
73000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
68000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
538390000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
519620000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-130000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-923000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-350763000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-248893000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
187570000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
269872000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
221235000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
299568000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7000000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
85697000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51009000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38935000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26540000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20153000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15724000
CY2023 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
6187000
CY2022 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0
CY2021 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0
CY2023 us-gaap Operating Expenses
OperatingExpenses
118424000
CY2022 us-gaap Operating Expenses
OperatingExpenses
71162000
CY2021 us-gaap Operating Expenses
OperatingExpenses
54659000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-111424000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-71162000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-54659000
CY2023 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
11104000
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4108000
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
188000
CY2023 us-gaap Interest Expense
InterestExpense
1550000
CY2022 us-gaap Interest Expense
InterestExpense
1185000
CY2021 us-gaap Interest Expense
InterestExpense
159000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-101870000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-68239000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-54630000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.4
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.4
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.01
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.01
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.04
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.04
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72553645
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72553645
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67368935
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67368935
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52759335
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52759335
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-101870000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-68239000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-54630000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-49000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-50000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
795000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-583000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-104000
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
793000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-632000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-154000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-101077000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68871000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54784000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
140978000
CY2021 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2070000
CY2021 kzr Adjustments To Additional Paid In Capital Share Based Compensation Vesting Related To Shares Of Common Stock Issued Pursuant To Early Exercises
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingRelatedToSharesOfCommonStockIssuedPursuantToEarlyExercises
21000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7596000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-154000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-54630000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
196876000
CY2022 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1319000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14006000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-632000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-68239000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
269872000
CY2023 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
638000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18137000
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
793000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-101870000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
187570000
CY2023 us-gaap Profit Loss
ProfitLoss
-101870000
CY2022 us-gaap Profit Loss
ProfitLoss
-68239000
CY2021 us-gaap Profit Loss
ProfitLoss
-54630000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1066000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1023000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1510000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
18137000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
14006000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
7596000
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
6830000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1401000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1770000
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
235000
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
212000
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
91000
CY2023 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
208000
CY2022 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2021 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2023 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
2700000
CY2022 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2021 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-12000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3583000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5787000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1051000
CY2023 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
4921000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
392000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6347000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1814000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1217000
CY2023 kzr Increase Decrease In Operating Lease Asset And Liabilities
IncreaseDecreaseInOperatingLeaseAssetAndLiabilities
303000
CY2022 kzr Increase Decrease In Operating Lease Asset And Liabilities
IncreaseDecreaseInOperatingLeaseAssetAndLiabilities
94000
CY2021 kzr Increase Decrease In Operating Lease Asset And Liabilities
IncreaseDecreaseInOperatingLeaseAssetAndLiabilities
1042000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-81645000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58846000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42437000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1810000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1578000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
316000
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
180399000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
332203000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
156378000
CY2023 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
258250000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
242389000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
128250000
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
5000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
76046000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-91392000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28444000
CY2023 kzr Proceeds From Issuance Of Common Stock Under At The Market Offerings And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockUnderAtTheMarketOfferingsAndWarrantsNetOfIssuanceCosts
0
CY2022 kzr Proceeds From Issuance Of Common Stock Under At The Market Offerings And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockUnderAtTheMarketOfferingsAndWarrantsNetOfIssuanceCosts
126542000
CY2021 kzr Proceeds From Issuance Of Common Stock Under At The Market Offerings And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockUnderAtTheMarketOfferingsAndWarrantsNetOfIssuanceCosts
100970000
CY2023 kzr Debt Discount And Issuance Costs
DebtDiscountAndIssuanceCosts
469000
CY2023 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2022 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
9531000
CY2023 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
638000
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1319000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2084000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
638000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
127861000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
112585000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-49000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-50000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4963000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22426000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41654000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40456000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62882000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21228000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35493000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40456000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62882000
CY2023 kzr Reclassification Of Employee Stock Liability To Equity Upon Vesting
ReclassificationOfEmployeeStockLiabilityToEquityUponVesting
0
CY2022 kzr Reclassification Of Employee Stock Liability To Equity Upon Vesting
ReclassificationOfEmployeeStockLiabilityToEquityUponVesting
0
CY2021 kzr Reclassification Of Employee Stock Liability To Equity Upon Vesting
ReclassificationOfEmployeeStockLiabilityToEquityUponVesting
21000
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
47000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
442000
CY2023 kzr Par Value Of Common Stock Upon Cashless Exercise Of Prefunded Warrants
ParValueOfCommonStockUponCashlessExerciseOfPrefundedWarrants
4000
CY2022 kzr Par Value Of Common Stock Upon Cashless Exercise Of Prefunded Warrants
ParValueOfCommonStockUponCashlessExerciseOfPrefundedWarrants
0
CY2021 kzr Par Value Of Common Stock Upon Cashless Exercise Of Prefunded Warrants
ParValueOfCommonStockUponCashlessExerciseOfPrefundedWarrants
0
CY2023 us-gaap Interest Paid Net
InterestPaidNet
1315000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
973000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
69000
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-350800000
CY2022 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
11911699
CY2022 kzr Common Stock Weighted Average Purchase Price Per Share
CommonStockWeightedAveragePurchasePricePerShare
10.95
CY2021 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9352359
CY2021 kzr Common Stock Weighted Average Purchase Price Per Share
CommonStockWeightedAveragePurchasePricePerShare
11.13
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such judgments, estimates and assumptions include the valuation of marketable securities, impairment of long-lived assets, determining the fair-value of stock-based compensation, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">evaluating the progress to completion of external research and development costs. Management bases its estimates on historical experience and on various other market-specific relevant assumptions that management believes to be reasonable under the circumstances. Actual results may differ from those estimates.</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s consolidated financial statements.</span></p>
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
0
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">instruments that potentially expose the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. As of December 31, 2023, the majority of the Company’s cash, cash equivalents and marketable securities were held by financial institutions in the United States,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">while </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was held by a financial institution in Australia. Such deposits in the United States were in excess of insured limits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023 kzr Interest Rate Of Sublease Income Per Year
InterestRateOfSubleaseIncomePerYear
0.035
CY2023 kzr Discount Rate Of Cash Flow
DiscountRateOfCashFlow
0.133
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2022Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
76102000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
103000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
182408000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
722000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
11849000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
14000
CY2023Q4 kzr Debt Securities Avalilable For Sale Credit Related Losses
DebtSecuritiesAvalilableForSaleCreditRelatedLosses
0
CY2023 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
186428000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
186477000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
14684000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
14751000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
201112000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
201228000
CY2023Q4 kzr Prepaid Advance For Clinical Related Costs Current
PrepaidAdvanceForClinicalRelatedCostsCurrent
1818000
CY2022Q4 kzr Prepaid Advance For Clinical Related Costs Current
PrepaidAdvanceForClinicalRelatedCostsCurrent
6760000
CY2023Q4 kzr Prepaid License Dues And Subscription
PrepaidLicenseDuesAndSubscription
506000
CY2022Q4 kzr Prepaid License Dues And Subscription
PrepaidLicenseDuesAndSubscription
376000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
712000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
741000
CY2023Q4 kzr Receivable From Collaboration
ReceivableFromCollaboration
1596000
CY2022Q4 kzr Receivable From Collaboration
ReceivableFromCollaboration
0
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
695000
CY2022Q4 us-gaap Interest Receivable
InterestReceivable
774000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
251000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
510000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5578000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9161000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9332000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8033000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5420000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4602000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3912000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3431000
CY2023 us-gaap Depreciation
Depreciation
1100000
CY2022 us-gaap Depreciation
Depreciation
1000000
CY2021 us-gaap Depreciation
Depreciation
900000
CY2023Q4 kzr Impairment Charges Property Plant And Equipment
ImpairmentChargesPropertyPlantAndEquipment
200000
CY2023Q4 kzr Other Assets Advance For Clinical Related Costs Non Current
OtherAssetsAdvanceForClinicalRelatedCostsNonCurrent
4787000
CY2022Q4 kzr Other Assets Advance For Clinical Related Costs Non Current
OtherAssetsAdvanceForClinicalRelatedCostsNonCurrent
0
CY2023Q4 kzr Other Assets Deposits For Operating Lease
OtherAssetsDepositsForOperatingLease
674000
CY2022Q4 kzr Other Assets Deposits For Operating Lease
OtherAssetsDepositsForOperatingLease
674000
CY2023Q4 us-gaap Other Assets Miscellaneous
OtherAssetsMiscellaneous
134000
CY2022Q4 us-gaap Other Assets Miscellaneous
OtherAssetsMiscellaneous
0
CY2023Q4 us-gaap Other Assets
OtherAssets
5595000
CY2022Q4 us-gaap Other Assets
OtherAssets
674000
CY2023Q4 kzr Accrued Preclinical And Research Costs Current
AccruedPreclinicalAndResearchCostsCurrent
756000
CY2022Q4 kzr Accrued Preclinical And Research Costs Current
AccruedPreclinicalAndResearchCostsCurrent
1368000
CY2023Q4 kzr Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
1801000
CY2022Q4 kzr Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
1007000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3708000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3260000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
110000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
53000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
106000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
265000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6481000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5953000
CY2023 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The operating lease agreement has one option to extend the lease term for a period of five years at the fair market rate at the time of the extension.
CY2023Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M29D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1167
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
2566000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1032000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1042000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
3464000
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2236553
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1557153
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1493000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1099000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
1502000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
807000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
765000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3890000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4025000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2418000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10333000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1469000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
8864000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3012000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5852000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
8864000
CY2023 kzr Lease And Rental Expense1
LeaseAndRentalExpense1
3500000
CY2022 kzr Lease And Rental Expense1
LeaseAndRentalExpense1
1500000
CY2021 kzr Lease And Rental Expense1
LeaseAndRentalExpense1
1100000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
1500000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
800000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
800000
CY2023 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
2700000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
243000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
342000
CY2023Q4 kzr Cumulative Accretion Of Final Fee
CumulativeAccretionOfFinalFee
312000
CY2022Q4 kzr Cumulative Accretion Of Final Fee
CumulativeAccretionOfFinalFee
176000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10069000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9834000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
5217000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
4783000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
10000000
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2023Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P20Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9684810
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.12
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15407000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5808994
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.56
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
155871
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.65
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
376000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2227216
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.26
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13110717
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.60
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
118000
CY2023Q4 kzr Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber
7093081
CY2023Q4 kzr Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice
2.66
CY2023 kzr Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm
P5Y7M6D
CY2023Q4 kzr Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue
10000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
400000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1500000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18137000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14006000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7596000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
1400000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-101870000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-68239000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-54630000
CY2015Q4 kzr Research And Development Tax Credit Maximum Utilization Against Employers Portion Of Payroll Tax
ResearchAndDevelopmentTaxCreditMaximumUtilizationAgainstEmployersPortionOfPayrollTax
250000
CY2023 kzr Research And Development Tax Credit Utilized As Reduction Of Payroll Expenses
ResearchAndDevelopmentTaxCreditUtilizedAsReductionOfPayrollExpenses
0
CY2022 kzr Research And Development Tax Credit Utilized As Reduction Of Payroll Expenses
ResearchAndDevelopmentTaxCreditUtilizedAsReductionOfPayrollExpenses
79000
CY2021 kzr Research And Development Tax Credit Utilized As Reduction Of Payroll Expenses
ResearchAndDevelopmentTaxCreditUtilizedAsReductionOfPayrollExpenses
325000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.03
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.013
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.013
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.021
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.006
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.022
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.032
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.025
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.04
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.251
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.242
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.241
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
4692000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
3420000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
42984000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
37939000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
12032000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
7603000
CY2023Q4 kzr Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
1862000
CY2022Q4 kzr Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
2402000
CY2023Q4 kzr Deferredtaxassetsrdcapitalization
Deferredtaxassetsrdcapitalization
22248000
CY2022Q4 kzr Deferredtaxassetsrdcapitalization
Deferredtaxassetsrdcapitalization
7979000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
83818000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
59343000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
82541000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
56983000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1277000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2360000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
273000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
313000
CY2023Q4 kzr Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
1004000
CY2022Q4 kzr Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
2047000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
25600000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
15200000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12400000
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4100000
CY2023Q4 kzr Liability Related To Uncertain Tax Position
LiabilityRelatedToUncertainTaxPosition
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2522000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1643000
CY2023 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
222000
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
187000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1774000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1066000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4074000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2522000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-101870000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-68239000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-54630000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72553645
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67368935
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52759335
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.40
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.40
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.01
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.01
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.04
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.04
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13330326
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10119600
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6945184
CY2023 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
6200000
CY2023 us-gaap Severance Costs1
SeveranceCosts1
3279000
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
2908000
CY2023 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
6187000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023 us-gaap Restructuring Charges
RestructuringCharges
6187000
CY2023 us-gaap Payments For Restructuring
PaymentsForRestructuring
1858000
CY2023 us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
2908000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
1421000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
1400000

Files In Submission

Name View Source Status
0000950170-24-031494-index-headers.html Edgar Link pending
0000950170-24-031494-index.html Edgar Link pending
0000950170-24-031494.txt Edgar Link pending
0000950170-24-031494-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img39262056_0.jpg Edgar Link pending
kzr-20231231.htm Edgar Link pending
kzr-20231231.xsd Edgar Link pending
kzr-ex10_11.htm Edgar Link pending
kzr-ex23_1.htm Edgar Link pending
kzr-ex31_1.htm Edgar Link pending
kzr-ex31_2.htm Edgar Link pending
kzr-ex32_1.htm Edgar Link pending
kzr-ex4_2.htm Edgar Link pending
kzr-ex97_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
kzr-20231231_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending